Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BMEA

Biomea Fusion (BMEA)

Biomea Fusion Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BMEA
DateTimeSourceHeadlineSymbolCompany
14/06/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
13/06/202407:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
13/06/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
08/06/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
07/06/202406:05GlobeNewswire Inc.Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical HoldNASDAQ:BMEABiomea Fusion Inc
04/06/202406:05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
30/05/202423:12GlobeNewswire Inc.Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 DiabetesNASDAQ:BMEABiomea Fusion Inc
03/05/202406:05GlobeNewswire Inc.Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
02/05/202406:10GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
02/04/202407:10GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
02/04/202400:02GlobeNewswire Inc.Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219NASDAQ:BMEABiomea Fusion Inc
02/04/202400:00GlobeNewswire Inc.Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
08/03/202408:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
06/03/202419:04GlobeNewswire Inc.Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionNASDAQ:BMEABiomea Fusion Inc
02/03/202408:16GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
13/02/202409:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BMEABiomea Fusion Inc
19/01/202408:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
19/01/202408:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
11/01/202408:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
10/01/202403:02GlobeNewswire Inc.Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
09/01/202401:00GlobeNewswire Inc.Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219NASDAQ:BMEABiomea Fusion Inc
06/01/202408:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BMEABiomea Fusion Inc
03/01/202408:05GlobeNewswire Inc.Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
12/12/202301:25GlobeNewswire Inc.Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASHNASDAQ:BMEABiomea Fusion Inc
10/12/202309:30GlobeNewswire Inc.Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose CohortsNASDAQ:BMEABiomea Fusion Inc
09/12/202301:00GlobeNewswire Inc.Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin ResistaNASDAQ:BMEABiomea Fusion Inc
08/12/202301:15GlobeNewswire Inc.Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular DiseNASDAQ:BMEABiomea Fusion Inc
06/12/202300:30GlobeNewswire Inc.Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 DiabetesNASDAQ:BMEABiomea Fusion Inc
28/11/202300:30GlobeNewswire Inc.Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024NASDAQ:BMEABiomea Fusion Inc
17/11/202300:30GlobeNewswire Inc.Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular DiseaseNASDAQ:BMEABiomea Fusion Inc
 Showing the most relevant articles for your search:NASDAQ:BMEA